• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Parkinson disease protein 7 (PARK7), Truncated

Introducing the Recombinant Human Parkinson Disease Protein 7 (PARK7), a vital tool for advancing your cancer research endeavors. PARK7, a multifunctional protein, is implicated in various cellular processes, including oxidative stress response, cell proliferation, and apoptosis. Its dysregulation has been linked to several cancer types and neurodegenerative diseases, such as Parkinson's disease. Our Recombinant Human PARK7 protein is expressed in E. coli, ensuring high levels of stability and bioactivity. The protein encompasses a partial sequence (1-174aa) and features an N-terminal 6xHis-SUMO tag for efficient purification and detection. With a purity of greater than 90% as determined by SDS-PAGE, our PARK7 protein offers consistent performance across a wide range of experimental applications. Choose between liquid or lyophilized powder forms to suit your laboratory needs, and trust in our precision-engineered Recombinant Human PARK7 protein to provide reliable results for your cancer research.

ACP03781

Introducing the Recombinant Human Parkinson Disease Protein 7 (PARK7), a vital tool for advancing your cancer research endeavors. PARK7, a multifunctional protein, is implicated in various cellular processes, including oxidative stress response, cell proliferation, and apoptosis. Its dysregulation has been linked to several cancer types and neurodegenerative diseases, such as Parkinson’s disease.
Our Recombinant Human PARK7 protein is expressed in E. coli, ensuring high levels of stability and bioactivity. The protein encompasses a partial sequence (1-174aa) and features an N-terminal 6xHis-SUMO tag for efficient purification and detection. With a purity of greater than 90% as determined by SDS-PAGE, our PARK7 protein offers consistent performance across a wide range of experimental applications. Choose between liquid or lyophilized powder forms to suit your laboratory needs, and trust in our precision-engineered Recombinant Human PARK7 protein to provide reliable results for your cancer research.

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP03781 Target NamePARK7
Target Synonymsearly onset) 7; Parkinson disease protein 7; Parkinson protein 7; Protein DJ-1; SP22FormLiquid or Lyophilized powder
Expression SystemE.coliExpression Range1-174aa
Mol Weight34.3kDaProtein LengthPartial
PurityGreater than 90% as determined by SDS-PAGE.Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ99497
Background Information
  • Uniprot Id

    Q99497

  • Target Species

    Human

  • Target Name

    PARK7

  • Target Full Name

    Parkinson disease protein 7

  • Target Function

    Multifunctional protein with controversial molecular function which plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease. It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulator of androgen signaling pathway as well as cell growth and transformation through, for instance, the modulation of NF-kappa-B signaling pathway. Has been described as a protein and nucleotide deglycase that catalyzes the deglycation of the Maillard adducts formed between amino groups of proteins or nucleotides and reactive carbonyl groups of glyoxals. But this function is rebuted by other works. As a protein deglycase, repairs methylglyoxal- and glyoxal-glycated proteins, and releases repaired proteins and lactate or glycolate, respectively. Deglycates cysteine, arginine and lysine residues in proteins, and thus reactivates these proteins by reversing glycation by glyoxals. Acts on early glycation intermediates (hemithioacetals and aminocarbinols), preventing the formation of advanced glycation endproducts (AGE) that cause irreversible damage. Also functions as a nucleotide deglycase able to repair glycated guanine in the free nucleotide pool (GTP, GDP, GMP, dGTP) and in DNA and RNA. Is thus involved in a major nucleotide repair system named guanine glycation repair (GG repair), dedicated to reversing methylglyoxal and glyoxal damage via nucleotide sanitization and direct nucleic acid repair. Protects histones from adduction by methylglyoxal, controls the levels of methylglyoxal-derived argininine modifications on chromatin. Able to remove the glycations and restore histone 3, histone glycation disrupts both local and global chromatin architecture by altering histone-DNA interactions as well as histone acetylation and ubiquitination levels. Displays a very low glyoxalase activity that may reflect its deglycase activity. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. Required for correct mitochondrial morphology and function as well as for autophagy of dysfunctional mitochondria. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Regulates astrocyte inflammatory responses, may modulate lipid rafts-dependent endocytosis in astrocytes and neuronal cells. In pancreatic islets, involved in the maintenance of mitochondrial reactive oxygen species (ROS) levels and glucose homeostasis in an age- and diet dependent manner. Protects pancreatic beta cells from cell death induced by inflammatory and cytotoxic setting. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Metal-binding protein able to bind copper as well as toxic mercury ions, enhances the cell protection mechanism against induced metal toxicity. In macrophages, interacts with the NADPH oxidase subunit NCF1 to direct NADPH oxidase-dependent ROS production, and protects against sepsis.

  • Target Involvement

    Parkinson disease 7 (PARK7)

  • Target Subcellular Location

    Cell membrane; Lipid-anchor. Cytoplasm. Nucleus. Membrane raft. Mitochondrion. Endoplasmic reticulum.

  • Target Protein Families

    Peptidase C56 family

  • Target Tissue Specificity

    Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain (at protein level). Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Expressed by panc

  • Target Research Area

    Apoptosis, Cancer

  • Target Synonyms

    CAP1; DJ-1; DJ1; DJ1 protein ; Epididymis secretory sperm binding protein Li 67p; FLJ27376; FLJ34360; FLJ92274; HEL S 67p; Oncogene DJ1; OTTHUMP00000001348; OTTHUMP00000001349; OTTHUMP00000001350; OTTHUMP00000001351; PARK7; PARK7_HUMAN; Parkinson disease (autosomal recessive, early onset) 7; Parkinson disease protein 7; Parkinson protein 7; Protein DJ-1; SP22

  • Target Background

    The product of this gene belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. Defects in this gene are the cause of autosomal recessive early-onset Parkinson disease 7. Two transcript variants encoding the same protein have been identified for this gene.

Inquire Recombinant Human Parkinson disease protein 7 (PARK7), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification